Drs Kathy Miller and Francisco J. Esteva discuss testing and therapeutic options for the new classification of HER2-ultra-low breast cancer.

December 19, 2024 – Climb Bio, Inc. (Nasdaq: CLYM) today announced that the company will be added to the NASDAQ Biotech Index ...

The infant, Ridwan Habib Ilham, a resident of Jessore district of Bangladesh, was diagnosed with 'Craniosynostosis' in which ...

The parents could visit the hospital only once for a checkup following the surgery and one more physical consultation is ...

(NASDAQ:ARGX – Get Free Report) had its target price increased by equities research analysts at Wells Fargo & Company from ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study of suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor in people with ...

After hours: December 20 at 4:06:45 PM EST Loading Chart for ARGX ...

Androgen deprivation is the mainstay of advanced prostate cancer treatment. Despite initial responses, almost all patients progress to castration-resistant prostate cancer (CRPC). The ...

Impact and progress Frontiers' impact Progress Report 2022 All progress reports ...

Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including acute and ...